The complaint alleges that Embecta violated the Securities Exchange Act of 1934 by issuing false and misleading statements to shareholders. According to the litigation, the company provided fiscal guidance for the second quarter and full-year 2026 while failing to disclose significant headwinds, specifically within the pen needle market. These omissions allegedly left investors with a false impression of the company's financial health, leading to losses once the actual market conditions were revealed.
Investors Urged to Join Securities Fraud Lawsuit Against Embecta Corp.
Investors who held Embecta Corp. stock between November 25, 2025, and May 4, 2026, face an August 17, 2026, deadline to participate in a class action lawsuit. Schall, Brown & Schwartz LLP is seeking lead plaintiffs for the action, which alleges the company misled the market regarding its fiscal guidance.
Schall, Brown & Schwartz LLP, based in Los Angeles, is managing the case and advising shareholders that they do not need to be appointed as lead plaintiff to recover damages. Interested parties can reach out to Brian Schall or David Schwartz at 310-301-3335 or via the firm’s website to discuss potential participation. The class has not yet been certified, meaning investors who take no action will remain absent class members until further developments in the court process.
Comments (0)
No comments yet. Be the first!